CA-PACSCI-EMC
17.3.2020 15:02:07 CET | Business Wire | Press release
Pacific Scientific Energetic Materials Company (California), LLC. (PacSci EMC) announced today the execution of a Memorandum of Understanding with Space Information Laboratories (SIL) to provide plug-and-play Autonomous Flight Termination Systems (AFTS) for launch vehicles, missiles, hypersonic vehicles, reentry vehicles, strike weapons and unmanned aerial systems. PacSci EMC Safe and Arm high voltage electronics will be integrated with the SIL Vehicle Based Independent Tracking System (VBITS) AFTU with internal GPS L1/L2 Receivers, IMU, together in a Consolidated Avionics® unit with reduced Space, Weight and Power (SWAP) requirements. Attributes include open, modular, stackable and reconfigurable (OMSR) avionics.
“SIL has very unique, leading-edge technology for the AFSS mission that when combined with the PacSci EMC flight qualified ordnance flight termination system provides a low cost, comprehensive solution for this critical need,” said Greg Scaven, President, PacSci EMC. “The AFSS architecture is RCC-319 compliant with the flexibility and safety necessary for platform success, and the system can be customized for unique applications.”
SIL is a leading provider of high-end Li-Ion Polymer Intelli-Pack® Avionics/Telemetry and FTS Batteries, VBITS GPS Tracking and Autonomous Flight Termination Systems (AFTS), Space Based Range, and Consolidated Avionics® flight units for DoD programs of national significance. Originally developed in 2006, VBITS has successfully flown many times without loss of GPS receiver lock and this heritage is being leveraged. SIL’s patented Vehicles Based Independent Range System (VBIRS) will track, destroy and send high data rate BLOS telemetry without the need for ground range instrumentation Radar, Flight Termination and/or Telemetry Systems, and thus greatly reduces launch, and weapon system test and evaluation, costs.
Edmund Burke, President of Space Information Laboratories, said: “I am very impressed with PacSci EMC’s broad product offering and technical capabilities. They rapidly filled a need for us that will result in accelerated growth.”
About Pacific Scientific Energetic Materials Co.
PacSci EMC provides state-of-the-art safe and arm high voltage electronics firing circuitry for multiple DoD and commercial launch vehicle, missile, weapons and aircraft. PacSci EMC missile control safety and arming products are suitable for application in all weapon systems. PacSci EMC has seven decades of pyrotechnic and energetic materials experience for mission and flight critical safety systems. (https://psemc.com )
About Space Information Laboratories
Headquartered in Santa Maria, CA near Vandenberg AFB, SIL is a world-class small business supplier of innovative avionics and power system technologies and solutions for mission-critical programs for the MDA, NAVAIR, USAF, DARPA, Aerospace Industry, and other U.S. Government Agencies. SIL’s expertise includes development and production of Li-Ion Polymer Intelli-Pack® batteries, Intelli-Avionics®, VBITS GPS Tracking and Autonomous Flight Termination System, Space Based Range and Chameleon 12U to 27U Flexible Bus product lines. SIL is AS9100D Quality Management System certified to design, manufacture and test flight units. (www.spaceinformationlabs.com )
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005002/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom